<DOC>
	<DOCNO>NCT02058368</DOCNO>
	<brief_summary>This multicentre , randomise , double-blind , parallel group study Asian subject . The aim study investigate whether combination therapy dutasteride tamsulosin effective tamsulosin monotherapy improvement symptom health outcome risk population benign prostatic hyperplasia ( BPH ) clinical progression include old men ( &gt; =50 year ) , moderate-severe symptom BPH , enlarge prostate ( &gt; =30 cubicentimeter [ cc ] ) prostate specific antigen ( PSA ) &gt; = 1.5 nanogram per milliliter ( ng/mL ) . Each subject meet eligibility criterion screen enter four-week single-blind , placebo run-in period follow subject randomise 2 year double-blind treatment phase . The total study duration subject 110 week .</brief_summary>
	<brief_title>Study Compare Efficacy Safety Combination Treatment With Dutasteride Tamsulosin With Tamsulosin Monotherapy , Men With Moderate Severe Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Males , age &gt; =50 year Clinical diagnosis BPH medical history physical examination , include digital rectal examination ( DRE ) International Prostate Symptom Score ( IPSS ) &gt; =12 point Screening Prostate volume &gt; =30cc ( TRUS ) Total serum Prostate Specific Antigen ( PSA ) &gt; =1.5ng/mL &lt; = 10 ng/mL Screening Maximum urinary flow rate ( Qmax ) &gt; 5mL/sec 15mL/sec minimum void volume &gt; =125 milliliter ( mL ) Screening Asparate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Fluent literate local language ability comprehend record information IPSS , BPHrelated Health Status ( BHS ) , BPH Impact Index ( BII ) , Problem Assessment Scale Sexual Function Inventory ( PAS SFI ) questionnaires Men female partner childbearing potential must agree use condom 6 month last dose ( applies country local product monograph dutasteride mandate condom use men female partner childbearing potential ) History evidence prostate cancer ( e.g . positive biopsy ultrasound , suspicious Digital Rectal Examination [ DRE ] ) . Patients suspicious ultrasound DRE negative biopsy within precede 6 month stable PSA eligible study . Note : If total serum PSA &gt; 4ng/mL unless PSA value stable least past 2 year , investigator make every appropriate effort exclude possibility prostate cancer , include consideration prostate biopsy . Previous prostatic surgery ( include TURP , laser , transrectal high intensity focus ultrasound ( HIFU ) , thermotherapy , transurethral needle ablation ( TUNA ) , balloon dilatation , stent replacement ) invasive procedure treat BPH . History flexible/rigid cystoscopy instrumentation urethra within 7 day prior Screening Visit . Catheterisation ( &lt; 10F ) acceptable time restriction . History AUR within 3 month prior Screening Visit . Postvoid residual volume &gt; 250mL ( suprapubic ultrasound ) Screening . Any condition BPH , may judgment investigator , result urinary symptom change flow rate ( e.g . neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute chronic prostatitis , acute chronic urinary tract infection ) . Unstable liver disease ( chronic stable hepatitis B C acceptable subject meet entry criterion ) . History renal insufficiency , serum creatinine &gt; 1.5 time upper limit normal Screening . Any unstable , serious coexist medical condition ( ) include , limited : 1 . Myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . 2 . Postural hypotension , dizziness , vertigo sign symptom orthostasis , opinion investigator could exacerbate tamsulosin result put subject risk injury . 3 . Any serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure opinion investigator GSK medical monitor . Investigator may consult GSK Medical Monitor condition could interfere subject 's safety 4 . History breast cancer clinical breast examination find suggestive malignancy . 5 . History malignancy within past five year , except basal cell carcinoma skin . Subjects priori malignancy evidence disease least past 5 year eligible . Current Previous Use follow medication : 1 . Use 5alphareductase inhibitor ( e.g . finasteride ) , drug antiandrogenic property ( e.g . spironolactone , flutamide , bicalutamide , cimetidine , ketoconazole , progestational agent ) , drug note gynaecomastia effect , could affect prostate volume , within 6 month precede historical TRUS Screening Visit throughout study ( study medication ) . Previous use dutasteride within 6 month baseline historical TRUS . 2 . Anabolic steroid ( subject must discontinue 6 month prior study entry eligible ) agree take duration study . 3 . Phytotherapy BPH within 2 week Screening Visit and/or predict need phytotherapy study . 4 . Use alphaadrenoreceptor blocker within 2 week Screening Visit ( i.e . indoramin , prazosin , terazosin , tamsulosin , alfuzosin , doxazosin , silodosin ) and/or predict need alpha blocker study prescribe tamsulosin . 5 . Use alphaadrenoreceptor agonist ( e.g . pseudoephedrine , phenylephedrine , ephedrine ) anticholinergic ( e.g . oxybutynin , tolterodine , darifenacin , solifenacin , propantheline ) cholinergics ( e.g . bethanecol chloride ) within 48 hour prior uroflowmetry assessment . Hypersensitivity alpha/beta adrenoreceptor blocker 5alphareductase inhibitor , chemicallyrelated drug . Participation investigational market drug trial within 30 day ( 5 halflives drug , whichever long ) precede Screening Visit and/or plan participate trial course study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Quality Life</keyword>
</DOC>